Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
ORGANIZATION
Time Ripe for Debate on Drug Spending Macroeconomic Indexing: INES
The Institute for New Era Strategy (INES) is calling for a renewed debate on introducing a macroeconomic indexing mechanism for drug spending, arguing that discussions should begin now as policymakers consider broader healthcare spending reforms. The push comes as the…
To read the full story
Related Article
- Ishin Deepens Debate on Healthcare Macroeconomic Indexing
May 25, 2026
- Ishin Proposes Macroeconomic Indexing for Healthcare as LDP Talks Resume
March 24, 2026
- Ex-Bureaucrats, Academics Trade Barbs over Macroeconomic Indexing; Will MOF Allow Rise in Drug Cost?
October 28, 2022
- Main Focus of INES Proposal Is Securing Resources to Reward Innovation, Not Macroeconomic Indexing
October 25, 2021
ORGANIZATION
- FIRM Backs Growth Roadmap, Expects Better Investment Climate
July 10, 2026
- JPMA Sees Honebuto Shifting toward Industry Promotion, Still Against Off-Year Cuts
July 10, 2026
- Labor Group Urges Govt to Scrap FY2027 Off-Year Drug Price Cuts
July 7, 2026
- Japan’s Contract Rep Workforce Hits Record High in FY2025
July 6, 2026
- Japan’s Generic Use Rate Climbs to 89.7% in FY2025: JGA
July 6, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…